Literature DB >> 17574889

Concomitant, specific determination of growth hormone and pegvisomant in human serum.

H Ørskov1, J Frystyk, C Nielsen, A T Hansen, J Weeke, J O L Jørgensen.   

Abstract

Growth hormone (GH) and the GH receptor blocker, pegvisomant are usually circulating in high concentration in pegvisomant treated acromegalic patients. This and the close similarity between the peptides make determination of either difficult. In the present methodological study, endogenous GH in serum is initially isolated and determined in a slightly modified commercial immunometric assay, whereafter the now GH free medium allows measurement of pegvisomant. Inter-individual steady state levels of serum pegvisomant vary remarkably in both acromegalic patients and healthy controls, while the intra-individual variations are negligible.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17574889     DOI: 10.1016/j.ghir.2007.05.001

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  2 in total

1.  Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects.

Authors:  Louise Moller; Helene Norrelund; Niels Jessen; Allan Flyvbjerg; Steen B Pedersen; Bruce D Gaylinn; Jianhua Liu; Michael O Thorner; Niels Moller; Jens Otto Lunde Jorgensen
Journal:  J Clin Endocrinol Metab       Date:  2009-10-09       Impact factor: 5.958

Review 2.  The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.

Authors:  Sanne E Franck; Linda Broer; Aart Jan van der Lely; Peter Kamenicky; Ignacio Bernabéu; Elena Malchiodi; Patric J D Delhanty; Fernando Rivadeneira; Sebastian J C M M Neggers
Journal:  Neuroendocrinology       Date:  2016-08-12       Impact factor: 4.914

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.